JP2014515356A5 - - Google Patents

Download PDF

Info

Publication number
JP2014515356A5
JP2014515356A5 JP2014511611A JP2014511611A JP2014515356A5 JP 2014515356 A5 JP2014515356 A5 JP 2014515356A5 JP 2014511611 A JP2014511611 A JP 2014511611A JP 2014511611 A JP2014511611 A JP 2014511611A JP 2014515356 A5 JP2014515356 A5 JP 2014515356A5
Authority
JP
Japan
Prior art keywords
composition
dry powder
value
vancomycin
max
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014511611A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014515356A (ja
JP6012716B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/038775 external-priority patent/WO2012159103A1/en
Publication of JP2014515356A publication Critical patent/JP2014515356A/ja
Publication of JP2014515356A5 publication Critical patent/JP2014515356A5/ja
Application granted granted Critical
Publication of JP6012716B2 publication Critical patent/JP6012716B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014511611A 2011-05-19 2012-05-21 乾燥粉末バンコマイシン組成物および関連する方法 Expired - Fee Related JP6012716B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161487971P 2011-05-19 2011-05-19
US61/487,971 2011-05-19
PCT/US2012/038775 WO2012159103A1 (en) 2011-05-19 2012-05-21 Dry powder vancomycin compositions and associated methods

Publications (3)

Publication Number Publication Date
JP2014515356A JP2014515356A (ja) 2014-06-30
JP2014515356A5 true JP2014515356A5 (enExample) 2015-06-18
JP6012716B2 JP6012716B2 (ja) 2016-10-25

Family

ID=47177374

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014511611A Expired - Fee Related JP6012716B2 (ja) 2011-05-19 2012-05-21 乾燥粉末バンコマイシン組成物および関連する方法

Country Status (11)

Country Link
EP (1) EP2709646A4 (enExample)
JP (1) JP6012716B2 (enExample)
KR (1) KR101763195B1 (enExample)
CN (1) CN103717231B (enExample)
AU (1) AU2012254999B2 (enExample)
BR (1) BR112013029803B1 (enExample)
CA (2) CA2981038C (enExample)
IL (1) IL229506B (enExample)
MX (1) MX346244B (enExample)
SG (1) SG195038A1 (enExample)
WO (1) WO2012159103A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2798263T3 (es) 2005-12-08 2020-12-10 Insmed Inc Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
WO2014085526A1 (en) 2012-11-29 2014-06-05 Insmed Incorporated Stabilized vancomycin formulations
EP3007689B1 (en) 2013-01-10 2018-03-07 Pulmokine, Inc. Non-selective kinase inhibitors
CN104043104B (zh) * 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
EP3054937B1 (en) * 2013-10-11 2023-07-26 Pulmokine, Inc. Spray dry formulations
CA2940560A1 (en) * 2014-02-28 2015-09-03 Algipharma As Use of alginate oligomers in the treatment of cystic fibrosis and other conditions associated with defective cftr ion channel function
CN106573037A (zh) 2014-03-14 2017-04-19 库蒂斯制药公司 用于万古霉素口服液的组合物和方法
PL3142643T3 (pl) 2014-05-15 2019-12-31 Insmed Incorporated Sposoby leczenia zakażeń płuc prątkami niegruźliczymi
KR102763211B1 (ko) 2014-11-06 2025-02-04 셀리아 파마슈티칼즈 에이피에스 글리코펩티드 조성물
CN107106585B (zh) * 2015-02-06 2021-01-01 杭州美南医药科技有限公司 万古霉素的水溶液制剂
GB201609940D0 (en) 2016-06-07 2016-07-20 Novabiotics Ltd Microparticles
KR20230093341A (ko) 2016-10-27 2023-06-27 풀모킨 인코포레이티드 폐고혈압을 치료하기 위한 병용 요법
CN106963939A (zh) * 2017-03-22 2017-07-21 永信药品工业(昆山)股份有限公司 盐酸万古霉素药物组合物及其制备方法
IL270685B (en) * 2017-05-22 2022-09-01 Insmed Inc Cleavable derivatives of lipoglycopeptide and their uses
EP3773505A4 (en) 2018-03-30 2021-12-22 Insmed Incorporated PROCESS FOR THE CONTINUOUS MANUFACTURING OF LIPOSOMAL MEDICINAL PRODUCTS
AU2019262117C1 (en) 2018-05-02 2024-12-05 Insmed Incorporated Methods for the manufacture of liposomal drug formulations
US20200115412A1 (en) * 2018-10-15 2020-04-16 Savara Inc. Separation of vancomycin and its degradation products
CA3116637A1 (en) 2018-10-17 2020-04-23 Novabiotics Limited Dosage regime

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES286422Y (es) 1982-10-08 1986-09-16 Glaxo Group Limited Dispositivo para administrar medicamentos a pacientes
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
PT83094B (pt) 1985-07-30 1993-07-30 Glaxo Group Ltd Dispositivos proprios para a administracao de medicamentos a pacientes
JPH03193735A (ja) * 1989-12-22 1991-08-23 Shionogi & Co Ltd グリコペプチド系抗生物質の安定化組成物
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
JP4142149B2 (ja) * 1997-07-10 2008-08-27 明治製菓株式会社 バンコマイシンの凍結乾燥製剤
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
CN1188111C (zh) * 1999-10-29 2005-02-09 耐科塔医药公司 分散性得到改进的干粉组合物
EP1992335A1 (en) * 2001-11-01 2008-11-19 Nektar Therapeutics Spray drying methods and compositions thereof
DE10358387A1 (de) * 2003-12-13 2005-07-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulver enthaltend niedermolekulares Dextran und Verfahren zu deren Herstellung
FR2872044B1 (fr) * 2004-06-28 2007-06-29 Flamel Technologies Sa Formulation pharmaceutique a base d'antibiotique sous forme microcapsulaire
EP2050437A1 (en) * 2007-10-15 2009-04-22 Laboratoires SMB Improved pharmaceutical dry powder compositions for inhalation.
CA2739897C (en) * 2008-10-07 2017-10-03 Mpex Pharmaceuticals, Inc. Aerosol fluoroquinolone formulations for improved pharmacokinetics
WO2010111641A2 (en) * 2009-03-26 2010-09-30 Pulmatrix, Inc. Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis
ES2625260T5 (es) * 2009-03-26 2020-07-29 Pulmatrix Operating Co Inc Formulaciones de polvo seco y métodos para el tratamiento de enfermedades pulmonares

Similar Documents

Publication Publication Date Title
JP2014515356A5 (enExample)
JP2016534153A5 (enExample)
CA2836643C (en) Dry powder vancomycin compositions and associated methods
JP2011201907A5 (enExample)
JP2011116788A5 (enExample)
CA2653403C (en) Lipoic acid pellets
JP2016534142A5 (enExample)
JP2016523250A5 (enExample)
AU2012254999A1 (en) Dry powder vancomycin compositions and associated methods
JP2012503668A5 (enExample)
JP2008280351A5 (enExample)
JP2015007131A5 (enExample)
RU2018144108A (ru) Никотиносодержащие частицы
JP2013508289A5 (enExample)
EA031255B1 (ru) Состав с отсроченным высвобождением, содержащий гранулы цистеамина, и способы его получения и применения
JP2011507838A5 (enExample)
JP2013505233A5 (enExample)
JP4465152B2 (ja) 味をマスキングした、顆粒及びコーティングされた顆粒剤
JP2012509922A5 (enExample)
JP2018514564A5 (enExample)
JPWO2019237028A5 (ja) 吸入のための組成物
RU2014115289A (ru) Композиция пазопаниба
RU2011107139A (ru) Фармацевтическая композиция, содержащая n-[3-хлор-4-[(3-фторфенил)метокси]фенил]-6-[5[[[2-(метилсульфонил)этил]амино]метил]-2-фурил]-4-хиназолинамин
EA026665B1 (ru) Твердые формы препаратов иматиниба, ресуспензируемые непосредственно перед применением
JP2016531138A5 (enExample)